[
    {
        "trial_id": "NCT06690996",
        "brief_title": "A Study of LY4005130 in Healthy Participants",
        "official_title": "A Phase 1, Randomized, Placebo-controlled, Investigator and Participant Blinded, Single-ascending Dose and Multiple-ascending Dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of LY4005130 in Healthy Participants.",
        "lillyAlias": [
            "J5D-MC-FPAB"
        ],
        "brief_summary": "The purpose of this study is to evaluate how well LY4005130 is tolerated and what side effects may occur in healthy participants. The study drug will be administered either subcutaneously (SC) (under the skin) or intravenously (IV) (into a vein in the arm). Blood tests will be performed to check how much LY4005130 gets into the bloodstream and how long it takes the body to eliminate it.\n\nPart A for the single-ascending doses (SAD) of the study will last about 12 weeks with 9 visits. Part B for the multiple-ascending doses (MAD) of the study will either last about 16 weeks with 13 visits or 20 weeks with 12 visits not counting the time for screening.",
        "trial_status": "RECRUITING",
        "phase": [
            "PHASE1"
        ],
        "diseases_list": [
            "Healthy"
        ],
        "drugs_list": [
            "LY4005130",
            "LY4005130",
            "Placebo",
            "Placebo"
        ],
        "enrollment": 140,
        "inclusion_criteria": "inclusion criteria: \n\n Are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, vital signs, and 12-lead (electrocardiogram) ECG. If any values are outside the normal range and considered to be significant, for example, elevated white blood cell count, the respective test may be repeated once at the discretion of the investigator without consultation with the sponsor\n If enrolled as Japanese or Chinese, the entry requirements are as follows:\n\n   To qualify as a participant of first-generation Japanese origin, the participant, the participant's biological parents, and all of the participant's biological grandparents must be of exclusive Japanese descent and born in Japan\n   To qualify as Chinese for the purpose of this study, all 4 of the participant's biological grandparents must be of exclusive Chinese descent and born in China\n Have a body weight 45 kilogram (kg) or greater and body mass index greater than 18 and less than 32 kilogram per square meter (kg/m\u00b2)",
        "exclusion_criteria": "exclusion criteria: \n\nAre an individual of childbearing potential (IOCBP)\nHave known allergies to LY4005130, related compounds, or any components of the formulation\nHave received a live vaccine within 28 days of screening or intend to do so during the study or within 28 days after the study\n\n  Non-live or inactivated vaccinations are allowed\n  Bacillus Calmette Guerin vaccine must not have been administered within 12 months before screening\nHad a surgical procedure within 12 weeks before screening;\n\n  during the study, or\n  within 28 days after the study\nHave a history of allergy to medications that could be used to treat infusion reactions, or to the drug excipients\nHave a history or presence of multiple or severe allergies, anaphylactic reaction to prescription or nonprescription drugs, significant history of atopy, or a history of severe posttreatment hypersensitivity reactions. These reactions include, but are not limited to, erythema multiforme major, linear immunoglobulin A dermatosis, toxic epidermal necrolysis, and exfoliative dermatitis\nHave a diagnosis or history of malignant disease within 5 years prior to screening, with the following exceptions\n\n  Basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of metastatic disease for 3 years, or\n  Cervical carcinoma in situ, with no evidence of recurrence within the 5 years prior to screening\nHave had breast cancer within the past 10 years\nHave a history of a primary immunodeficiency, splenectomy, or any underlying condition that predisposes the participant to infection that, in the opinion of the sponsor or investigator, poses an unacceptable risk to the participant\nHave a current or recent acute, active infection",
        "keywords": []
    },
    {
        "trial_id": "NCT04088396",
        "brief_title": "A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)",
        "official_title": "Open-Label, Randomized Study With a Tocilizumab Reference Arm to Evaluate Safety, Efficacy and Pharmacokinetics of Baricitinib in Children From 1 to Less Than 18 Years of Age With Systemic Juvenile Idiopathic Arthritis.",
        "lillyAlias": [
            "I4V-MC-JAHU"
        ],
        "brief_summary": "The reason for this study is to see if the study drug baricitinib is safe and effective in participants from 1 year to less than 18 years old with systemic juvenile idiopathic arthritis (sJIA). Participants are assigned to 1 of 2 cohorts. In cohort 1, participants will receive baricitinib or tocilizumab reference. In cohort 2, participants will receive baricitinib.",
        "trial_status": "RECRUITING",
        "phase": [
            "PHASE3"
        ],
        "diseases_list": [
            "Systemic Juvenile Idiopathic Arthritis"
        ],
        "drugs_list": [
            "Baricitinib",
            "Tocilizumab"
        ],
        "enrollment": 58,
        "inclusion_criteria": "inclusion criteria: \n\n Participants must have a diagnosis of systemic Juvenile Idiopathic Arthritis (sJIA) as defined by International League of Associations for Rheumatology (ILAR) criteria with onset before the age of 16 years\n Participants must have at least 2 active joints at screening and baseline\n Cohort 1 (IL-6 inhibitor therapy naive): Participants who are at least 1 year and less than 18 years of age, except in countries that restrict use of tocilizumab in participants less than 2 years of age\n Cohort 2 (open-label baricitinib): Participants who are at least 1 year and less than 18 years of age",
        "exclusion_criteria": "exclusion criteria: \n\nParticipants must not have polyarticular JIA (positive or negative for rheumatoid factor), extended oligoarticular JIA, enthesitis-related JIA, or juvenile psoriatic arthritis\nParticipants must not have persistent oligoarticular arthritis as defined by the ILAR criteria\nParticipants must not have a history or presence of any autoimmune inflammatory condition other than JIA\nParticipants must not have active anterior uveitis or are receiving concurrent treatment for anterior uveitis\nParticipants must not have active fibromyalgia or other chronic pain conditions that, in the investigator's opinion, would make it difficult to appropriately assess disease activity for the purposes of this study\nParticipants must not have biologic features of Macrophage Activation Syndrome (MAS) over the past 12 weeks\nParticipants must not have a current or recent (\\<4 weeks prior to baseline) clinically serious infection\nParticipants must not have a positive test for hepatitis B virus\nParticipants must not have evidence of active tuberculosis (TB) or untreated latent TB",
        "keywords": [
            "Systemic",
            "Fever",
            "Flare",
            "sJIA",
            "JIA"
        ]
    },
    {
        "trial_id": "NCT03773965",
        "brief_title": "A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis",
        "official_title": "A Phase 3 Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients From 1 Year to <18 Years of Age With Juvenile Idiopathic Arthritis (JIA)",
        "lillyAlias": [
            "I4V-MC-JAHX"
        ],
        "brief_summary": "The reason for this study is to see if the study drug baricitinib is safe and effective in the treatment of JIA in participants ages 1 to 17. This study is for participants that have been enrolled in studies I4V-MC-JAHV (NCT03773978) or I4V-MC-JAHU.",
        "trial_status": "RECRUITING",
        "phase": [
            "PHASE3"
        ],
        "diseases_list": [
            "Juvenile Idiopathic Arthritis"
        ],
        "drugs_list": [
            "Baricitinib"
        ],
        "enrollment": 190,
        "inclusion_criteria": "inclusion criteria: \n\n Participants must have completed a previous study of baricitinib for the treatment of JIA.",
        "exclusion_criteria": "exclusion criteria: \n\nParticipants must not have had a permanent discontinuation of baricitinib in the prior study.\nParticipants must have not developed an allergy to baricitinib.",
        "keywords": [
            "Polyarticular JIA",
            "Oligoarthritis",
            "Juvenile psoriatic arthritis (JPsA)",
            "Enthesitis-related juvenile idiopathic arthritis (ERA)",
            "Systemic JIA with and without systemic features"
        ]
    },
    {
        "trial_id": "NCT06153355",
        "brief_title": "A First-In-Human Study of LY3839840 in Healthy Participants",
        "official_title": "Single- and Multiple-Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of LY3839840 Following Oral Dosing in Healthy Participants",
        "lillyAlias": [
            "J4U-MC-KTAA"
        ],
        "brief_summary": "The main purpose of this first-in-human study to investigate the safety of LY3839840 in single and multiple doses, and how it's processed in the body when given in different amounts.",
        "trial_status": "RECRUITING",
        "phase": [
            "PHASE1"
        ],
        "diseases_list": [
            "Healthy"
        ],
        "drugs_list": [
            "LY3839840",
            "Placebo",
            "Midazolam"
        ],
        "enrollment": 178,
        "inclusion_criteria": "inclusion criteria: \n\nHealthy men and women. Women may only be included if they are of nonchildbearing potential\n\nFor Part C:\n\n\u2022 Part C of the study includes Chinese participants only. To qualify, the participants must be considered as native Chinese, defined as all the participant's biological grandparents being of Chinese origin\n\nFor Part D:\n\n Part D of the study includes Japanese participants only. To qualify, the participants must be first-generation Japanese, defined as the participant's biological parents, and all the participant's biological grandparents, being of exclusive Japanese descent, and being born in Japan\n Participants who are healthy as determined through medical evaluation including medical history, physical examination, laboratory tests, vital signs, and 12-lead (electrocardiogram ECG)\n Have a body mass index (BMI) of greater than or equal to 18 to less than or equal to 35 kilograms per square meter (kg/m\u00b2). For Parts C and D: BMI greater than or equal to 18 to less than or equal to 29 kilograms per square meter (kg/m\u00b2)\n Participants who have laboratory tests within the normal reference range for the population or CRU or have results with acceptable deviations that are judged by the investigator not to be clinically significant\n Have venous access sufficient to allow for blood sampling",
        "exclusion_criteria": "exclusion criteria: \n\nHave known allergies to LY3839840, related compounds, or any components of the formulation\nHave a history or presence of multiple or severe allergies, anaphylactic reaction to prescription or nonprescription drugs, or history of significant atopy\nHave a significant history of or current rheumatologic, cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine (such as Cushing syndrome, hyperthyroidism, hyperaldosteronism), hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the investigational medicinal product; or of interfering with the interpretation of data\nHave had any significant infections within 3 months prior to the screening visit, or develop any of these infections before the randomization visit.\nHave received \u22651 live vaccine within 28 days of screening, or intend to during the study, or \u226428 days after the study\nHad any surgical procedure (except for minor surgery requiring local or no anesthesia and without any complications or sequelae) within 12 weeks prior to screening, or intend to during the study, or \u226428 days after the study\nHad any malignancy within the past 5 years. Exceptions: successfully treated basal cell skin carcinoma or squamous cell skin carcinoma with no evidence of recurrence or metastatic disease within the past 3 years\nHave a history of a primary immunodeficiency, splenectomy, or any underlying condition that predisposes the participant to infection that, in the opinion of the sponsor or investigator, poses an unacceptable risk to the participant\nHave used, or intend to use, prescription or nonprescription medication within 14 days prior to dosing (or 5 half-lives - whichever is longer)\nAre currently enrolled in any other clinical study involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study\nHave participated in a clinical study involving an investigational product within the last 30 days of the final drug administration (or 5 half-lives - whichever is longer)\nShow evidence of active or latent TB\nAre females who are lactating or have a positive pregnancy test at screening or Day -1\nBlood donation of \u2265450 mL, or participation in a clinical study that required a blood volume of \u2265400 mL since the last study visit within the past 120 days",
        "keywords": []
    },
    {
        "trial_id": "NCT05723198",
        "brief_title": "A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata",
        "official_title": "A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of Baricitinib in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata",
        "lillyAlias": [
            "I4V-MC-JAIO"
        ],
        "brief_summary": "The main purpose of this study is to determine the efficacy and safety of baricitinib for the treatment of severe or very severe alopecia areata (hair loss) in children from 6 years to less than 18 years of age.\n\nThe study is divided into 4 periods, a 5-week Screening period, a 36-week Double-Blind Treatment Period, an approximately 2-year Long-term Extension Period, and a 4-week Post-treatment Follow-up period.",
        "trial_status": "RECRUITING",
        "phase": [
            "PHASE3"
        ],
        "diseases_list": [
            "Areata Alopecia",
            "Alopecia",
            "Hypotrichosis",
            "Hair Diseases",
            "Skin Diseases",
            "Pathological Conditions, Anatomical"
        ],
        "drugs_list": [
            "Baricitinib",
            "Placebo"
        ],
        "enrollment": 595,
        "inclusion_criteria": "inclusion criteria: \n\n Enrollment will be fully sequential by age group, with adolescents (12 to less than 18 years old) enrolling before children (6 to less than 12 years old).\n Have severe areata alopecia (AA) for at least 1 year\n Diagnosis for at least 1 year\n Current AA episode of at least 6 months' duration\n SALT score \u226550% at screening and baseline\n History of trial and failure with at least 1 available treatment (topical or other) for AA\n History of psychological counseling related to AA\n Current episode of severe AA of less than 8 years.\n\n   Note: Participants who have severe AA for \u22658 years may be enrolled if episodes of regrowth, spontaneous or under treatment, have been observed on the affected areas over the past 8 years.",
        "exclusion_criteria": "exclusion criteria: \n\nPrimarily \"diffuse\" type of AA (characterized by diffuse hair shedding).\nAre currently experiencing other forms of alopecia including, but not limited to trichotillomania, telogen effluvium, chemotherapy-induced hair loss, or any other concomitant conditions (for example, tinea capitis, psoriasis, lupus erythematosus, or secondary syphilis) that would interfere with evaluations of the effect of study medication on AA.\nAre largely or wholly incapacitated permitting little or no self-care, such as being bedridden\nHave uncontrolled arterial hypertension\nHave had major surgery within 8 weeks prior to screening or will require major surgery during the study\nHave a history or presence of cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, hematological, neurological, or neuropsychiatric disorders or any other serious and/or unstable illness that, in the opinion of the investigator, could constitute an unacceptable risk when taking IP or interfere with the interpretation of data.\nHave a positive test for hepatitis B virus (HBV) infection\nHave hepatitis C virus (HCV) infection (positive for anti hepatitis C antibody with confirmed presence of HCV ribonucleic acid \\[RNA\\]).\nHave evidence of human immunodeficiency virus (HIV) infection and/or positive HIV antibodies.",
        "keywords": []
    },
    {
        "trial_id": "NCT06859294",
        "brief_title": "A Study of LY3541860 in Adult Participants With Moderately to Severely Active Rheumatoid Arthritis",
        "official_title": "A Phase 2a, Single-Arm Study to Investigate the Efficacy and Safety of LY3541860 in Adult Participants With Moderately to Severely Active Rheumatoid Arthritis",
        "lillyAlias": [
            "J3K-MC-KIAC"
        ],
        "brief_summary": "The main purpose of this study is to evaluate the effects of LY3541860 in adult participants with moderately to severely active Rheumatoid Arthritis with inadequate response to a least one biologic disease-modifying antirheumatic drug (bDMARD)or targeted synthetic disease-modifying antirheumatic drug (tsDMARD).\n\nStudy participation is approximately 50 weeks, including a 6-week screening period, 24-week treatment period, and a 20-week safety follow up period.",
        "trial_status": "RECRUITING",
        "phase": [
            "PHASE2"
        ],
        "diseases_list": [
            "Rheumatoid Arthritis"
        ],
        "drugs_list": [
            "LY3541860"
        ],
        "enrollment": 40,
        "inclusion_criteria": "inclusion criteria: \n\n Have a diagnosis of adult-onset Rheumatoid Arthritis (RA) for at least 3 months prior to screening, as defined by the 2010 ACR/EULAR classification criteria.\n Have moderately to severely active RA, at screening (Visit 1) and baseline (Visit 2), defined by the presence of\n\n   \u22656 swollen joints based on 66 joint count (and \u22654 swollen joints on 28 joint count), and\n   \u22656 tender joints based on 68 joint count (and \u22654 tender joints on 28 joint count).\n Have active synovitis in \u22651 joint, in hands or wrists, of the investigator choosing at screening, having an MRI synovitis RAMRIS score of \u22652 as determined from the central reading of the images.",
        "exclusion_criteria": "exclusion criteria: \n\nHave a diagnosis or history of malignant disease within 5 years prior to baseline, with the exceptions of\n\n  basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of metastatic disease for 3 years, or\n  cervical carcinoma in situ, with no evidence of recurrence within the 5 years prior to baseline.\nHave estimated glomerular filtration rate (eGFR) of \\<45 milliliter per minute (mL/minute) from serum creatinine using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation.\nHave a current or recent active infection.\nHave presence of 1 or more significant concurrent medical conditions per investigator judgment, including but not limited to\n\n  poorly controlled diabetes or hypertension\n  chronic kidney disease Stage 3a or b, 4, or 5\n  symptomatic heart failure according to New York Heart Association Class 2, 3, or 4\n  myocardial infarction, unstable angina pectoris, stroke, or transient ischemic attack within the past 12 months before baseline\n  severe chronic pulmonary disease, for example, requiring oxygen therapy major chronic inflammatory disease or connective tissue disease other than RA, including but not limited to\n  systemic lupus erythematosus\n  psoriatic arthritis\n  axial spondyloarthritis, including ankylosing spondylitis and non-radiographic axial spondyloarthritis\n  reactive arthritis\n  gout\n  scleroderma\n  polymyositis\n  dermatomyositis\n  active fibromyalgia, or\n  multiple sclerosis\nHave received any prior B-cell targeted therapy (for example, anti-CD19 antibodies or anti-CD20 antibodies, such as rituximab).\nReceived corticosteroids, opioids, conventional disease-modifying antirheumatic drug (cDMARD), with changes in dose or have received Janus kinase (JAK) inhibitors within 28 days prior to the screening MRI or plan on receiving these drugs during the study.",
        "keywords": []
    },
    {
        "trial_id": "NCT05784246",
        "brief_title": "A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis",
        "official_title": "A Multicenter, Phase 3, Open-Label Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mirikizumab in Participants 2 Years to Less Than 18 Years of Age With Moderately to Severely Active Ulcerative Colitis",
        "lillyAlias": [
            "I6T-MC-AMBA"
        ],
        "brief_summary": "The main purpose of this study is to investigate efficacy, pharmacokinetics and safety of the drug in pediatric participants with moderately to severely active ulcerative colitis (UC).",
        "trial_status": "RECRUITING",
        "phase": [
            "PHASE3"
        ],
        "diseases_list": [
            "Ulcerative Colitis"
        ],
        "drugs_list": [
            "Mirikizumab IV",
            "Mirikizumab SC"
        ],
        "enrollment": 60,
        "inclusion_criteria": "inclusion criteria: \n\n Males or females weighing \u226510 kg and \u22652 and \\<18 years old at the time of consent for screening.\n Have moderate to severe UC.\n Have failed corticosteroids, biologics, (for example, anti-tumor necrosis factor (TNF) antibodies or anti-integrin antibodies), immunomodulators (for example, azathioprine, thiopurines or methotrexate) or Janus Kinase (JAK)-Inhibitor treatment.\n Have UC at least 3 months in duration before baseline, which includes endoscopic evidence of UC corroborated by a histopathology report.",
        "exclusion_criteria": "exclusion criteria: \n\nHave Crohn's disease, Inflammatory Bowel Disease Unclassified, ulcerative proctitis or primary sclerosing cholangitis.\nHave immune deficiency syndrome.\nPrevious bowel resection or intestinal surgery.\nEvidence of toxic megacolon.\nHistory or current evidence of cancer of the gastrointestinal tract.",
        "keywords": []
    },
    {
        "trial_id": "NCT05074420",
        "brief_title": "A Study of Baricitinib (LY3009104) in Children With COVID-19",
        "official_title": "A Multicenter, Open-Label, Pharmacokinetic and Safety Study of Baricitinib in Pediatric Patients From 1 Year to Less Than 18 Years Old Hospitalized With COVID-19",
        "lillyAlias": [
            "I4V-MC-KHAB"
        ],
        "brief_summary": "The purpose for this study is to determine if the study drug baricitinib is effective and safe in hospitalized pediatric participants with Coronavirus disease 2019 (COVID -19) and to confirm the dose.",
        "trial_status": "RECRUITING",
        "phase": [
            "PHASE3"
        ],
        "diseases_list": [
            "Covid19",
            "Corona Virus Infection"
        ],
        "drugs_list": [
            "Baricitinib"
        ],
        "enrollment": 24,
        "inclusion_criteria": "inclusion criteria: \n\n Hospitalized with coronavirus (SARS-CoV-2) infection.\n Male or female participants from 1 to \\<18 years of age.\n Requires supplemental oxygen and have chest imaging findings to confirm respiratory disease due to COVID-19 within 72 hours of study entry and enrollment.\n Supplemental oxygen including but not limited to: nasal cannula, mask, high flow devices, CPAP/BiPAP, invasive mechanical ventilation as well as ECMO.",
        "exclusion_criteria": "exclusion criteria: \n\nAre receiving biologic treatments (such as Tumor Necrosis Factor \\[TNF\\] inhibitors, interleukin inhibitors, T-cell or B-cell targeted therapies, interferon, or Janus kinase (JAK) inhibitors); or are receiving other immunosuppressants such that, in the opinion of the investigator, participating in the study would put the participant at an unacceptable risk of immunosuppression.\n\nNote: A washout period is required prior to screening.\n\nAre receiving strong inhibitors of Organic Anion Transporter 3 (OAT3) (such as probenecid) that cannot be discontinued at study entry.\nHave diagnosis of current active tuberculosis (TB) or, if known, latent TB treated for less than 4 weeks with appropriate anti-tuberculosis therapy per local guidelines (by history only, no screening tests required).\nSuspected serious, active bacterial, fungal, viral, or other infection (besides COVID-19) that in the opinion of the investigator could constitute a risk when taking investigational product.\nHave received any live vaccine within 4 weeks before screening, or intend to receive a live vaccine during the study. Note: Use of non-live (inactivated) vaccinations are allowed for all participants.\nRequire invasive mechanical ventilation, including extracorporeal membrane oxygenation (ECMO) at study entry.\nCurrent diagnosis of active malignancy that, in the opinion of the investigator, could constitute a risk when taking investigational product.\nHave a history of venous thromboembolism (VTE) (deep vein thrombosis \\[DVT\\] and/or pulmonary embolism \\[PE\\]) or considered high risk of VTE (DVT/PE).\nAnticipated discharge from the hospital, or transfer to another hospital (or another unit), which is not a study site within 72 hours after study entry.\nHave neutropenia (absolute neutrophil count \\<1000 cells/microliters).\nHave lymphopenia (absolute lymphocyte count \\<200 cells/microliters).\nHave alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\>5 times AAULN.\nEstimated glomerular filtration rate (eGFR) (Modification of Diet in Renal Disease \\[MDRD\\]) \\<40 milliliter/minute/1.73 meters squared.\nHave a known hypersensitivity to baricitinib or any of its excipients.\nAre currently enrolled in any other clinical study involving an investigation product or any other type of medical research judged not to be scientifically or medically compatible with this study. Note: The participant should not be enrolled (started) in another clinical trial for the treatment of COVID-19 or SARS CoV-2 through Day 28.\nAre pregnant, or intend to become pregnant or breastfeed during the study.\nAre, in the opinion of the investigator or sponsor, at risk of immunosuppression or otherwise unsuitable for inclusion in the study.\nAre using or will use extracorporeal blood purification (EBP) device to remove proinflammatory cytokines from the blood such as a cytokine absorption or filtering device, for example, CytoSorb\u00ae.\nAre, in the opinion of the investigator, unlikely to survive for at least 48 hours after screening.",
        "keywords": [
            "coronavirus"
        ]
    },
    {
        "trial_id": "NCT06395012",
        "brief_title": "A First-In-Human Study of LY3985297 in Healthy Participants",
        "official_title": "A Phase 1, Randomized, Placebo-controlled, Investigator and Participant Blinded, Single Ascending Dose and Multiple Ascending Dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of LY3985297 in Healthy Participants",
        "lillyAlias": [
            "J4S-MC-KSAA"
        ],
        "brief_summary": "The main purpose of this study is to see if LY3985297, the study drug, is safe and well-tolerated when given as a single dose or as multiple doses either through an intravenous (into a vein) or a subcutaneous (under the skin) injection in healthy participants. Study will also evaluate how much of the study drug LY3985297 gets into the blood stream and how long it takes the body to remove it.\n\nThe study is conducted in two parts (part A and B), each part has a separate treatment cohort.\n\nThe study will last up to approximately 116 days for part A, and 145 days for part B, including the screening period.",
        "trial_status": "RECRUITING",
        "phase": [
            "PHASE1"
        ],
        "diseases_list": [
            "Healthy"
        ],
        "drugs_list": [
            "LY3985297",
            "Placebo"
        ],
        "enrollment": 153,
        "inclusion_criteria": "inclusion criteria: \n\n Participants must be overtly healthy, as determined by medical evaluation.\n Have a body mass index of 18.0 to 32.0 kilograms per square meter (kg/m\u00b2), inclusive, and a minimum body weight of 45.0 kg.\n Participants must be assigned male or female at birth and not of childbearing potential.\n Have normal blood pressure, pulse rate, electrocardiogram (ECG), clinical laboratory test results that are acceptable for the study.\n Have venous access sufficient to allow for blood sampling.\n\nFor Part A Cohorts 5, 6, and 7:\n\n Participants must be first-generation Japanese only, defined as the participant's biological parents, and all of the participant's biological grandparents must be of exclusive Japanese descent and born in Japan. Or\n Participants must be first-generation Chinese only, defined as the participant's biological parents, and all of the participant's biological grandparents must be of exclusive Chinese descent and born in China.",
        "exclusion_criteria": "exclusion criteria: \n\nHave a current or recent acute, active infection. For at least 30 days before screening and up to the randomization visit (Day 1).\nHad any surgical procedure (except for minor surgery requiring local or no anesthesia and without any complications or sequelae) within 12 weeks prior to screening or intend to during the study.\nHave a history of multiple or severe allergies, or an anaphylactic reaction, to prescription or nonprescription drugs or food.\nShow evidence of active or latent tuberculosis (TB).\nHave one of the following infections: hepatitis B, C virus or human immunodeficiency virus (HIV).",
        "keywords": []
    },
    {
        "trial_id": "NCT05395481",
        "brief_title": "A Single-Ascending and Repeated Dose Study of LY3849891 in Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)",
        "official_title": "A Single-Ascending and Repeated Subcutaneous Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3849891 in Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Who Have the PNPLA3 I148M Genotype",
        "lillyAlias": [
            "J3W-MC-GZOA"
        ],
        "brief_summary": "The main purpose of this study is to evaluate the safety and tolerability of the study drug LY3849891 in participants with metabolic dysfunction-associated steatotic liver disease (MASLD) who have the patatin-like phospholipase domain-containing protein 3 (PNPLA3) I148M genotype. Blood tests and magnetic resonance imaging of the liver will be performed to determine the effects of LY3849891 on MASLD and assessment of resolution of liver fibroinflammation. Blood tests will also determine how long it takes the body to eliminate LY3849891. This is a 2-part study and may last up to 32 weeks for each participant and may include 12 visits in parts A and B.",
        "trial_status": "RECRUITING",
        "phase": [
            "PHASE1"
        ],
        "diseases_list": [
            "Metabolic Dysfunction-Associated Steatohepatitis (MASH)",
            "Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)"
        ],
        "drugs_list": [
            "LY3849891",
            "Placebo"
        ],
        "enrollment": 176,
        "inclusion_criteria": "inclusion criteria: \n\n Participants must have a body mass index (BMI) within the range greater than or equal to (\u2265) 25 and less than (\\<) 50 kilogram per square meter (kg/m\u00b2) inclusive\n Participants must have liver fat content \u226510% in Part A and \u22658% for Part B as determined by MRI-PDFF\n Participants must be carriers of the PNPLA3 I148M allele\n Participants with or without type 2 diabetes mellitus (T2DM)\n\n  o For participants with T2DM, hemoglobin A1c (HbA1c) \\<8% in Part A and \\<9% in Part B\n Male participants agree to use an effective method of contraception for the duration of the study and for 90 days after the last dose of study intervention\n Women not of childbearing potential may participate and include those who are: infertile due to surgical sterilization (hysterectomy, bilateral oophorectomy, or tubal ligation), congenital anomaly such as Mullerian agenesis; or those who are postmenopausal",
        "exclusion_criteria": "exclusion criteria: \n\nParticipants must not have known or suspected alcohol abuse (\\>14 units/week for women and \\>21 units/week for men) or active substance abuse\nParticipants must not have evidence of cirrhosis or other forms of liver disease\nParticipants must not have heart attack, stroke, or hospitalization for congestive heart failure in the past 3 months\nParticipants must not have active cancer within the last 5 years\nParticipants must not have uncontrolled high blood pressure\nParticipants must not have renal impairment with estimated glomerular filtration rate (eGFR) \\<60 milliliter per minute per 1.73 square meter (ml/min/1.73m\u00b2)\nParticipants must not have a diagnosis of type 1 diabetes\nParticipants must not have a contraindication to MRI examinations, such as persons with cardiac pacemaker and implants made out of metal (for example, cochlear implant, nerve stimulators, magnetic vascular clips, and metallic heart valve) or other contraindications for MRI",
        "keywords": [
            "Hepatic fibrosis",
            "Biomarkers",
            "Magnetic resonance imaging",
            "Pharmacokinetics",
            "Liver fat"
        ]
    }
]